Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14332609 | 0.84 | IRAK4 (0.36) | EPHB3UCHL1JAK2BTKIRAK4 | |
| SCHEMBL14332431 | 0.83 | LPL (0.36) | UCHL1JAK2BTKIRAK4FFAR1 | |
| SCHEMBL31383661 | 0.80 | PIK3CA (0.35) | UCHL1JAK2BTKIRAK4PIK3CD | |
| SCHEMBL24369880 | 0.79 | EPHB3 (0.36) | EPHB3UCHL1JAK2BTKIRAK4 | |
| SCHEMBL31383607 | 0.79 | PIK3CA (0.36) | UCHL1IRAK4PIK3CA | |
| SCHEMBL15717456 | 0.79 | UCHL1 (0.39) | UCHL1IRAK4KLKB1FFAR1 | |
| SCHEMBL1356211 | 0.78 | DRD3 (0.40) | EPHB3UCHL1IRAK4DRD4DRD3 | |
| SCHEMBL31383674 | 0.78 | PRMT5 (0.38) | EPHB3UCHL1IRAK4 | |
| SCHEMBL15717339 | 0.76 | UCHL1 (0.43) | EPHB3UCHL1PIK3CDPIK3CALIPE | |
| SCHEMBL15762383 | 0.76 | UCHL1 (0.39) | UCHL1KLKB1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | NEURO3 THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025029897-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | NEURO3 THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051363-A1 | Substituted Pyrazolopyridines | QDPR, DPYD, P2RX4 | EPHB3 2310/4885UCHL1 4338/4885JAK2 1829/4885 |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | EPHB3 4580/4885UCHL1 3174/4885JAK2 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.